N-Deshydroxyethyl Dasatinib

N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825) is a metabolite of Dasatinib, Dasatinib is a multi-kinase inhibitor that potently inhibits Bcr-Abl, Src family and platelet-derived growth factor receptor kinases. N-Deshydroxyethyl Dasatinib can be used in cancer and immune disease research[1][2].

Product Specifications

CAS Number

[910297-51-7]

Product Name Alternative

N-Deshydroxyethyl BMS-354825

UNSPSC

12352005

Hazard Statement

H315, H318, H351, H361, H372, H410

Target

Drug Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Target_Protein-binding_moiety_8.html

Purity

98.58

Solubility

DMSO : 55 mg/mL (ultrasonic)

Smiles

O=C(C1=CN=C(NC2=NC(C)=NC(N3CCNCC3)=C2)S1)NC4=C(C)C=CC=C4Cl

Molecular Formula

C20H22ClN7OS

Molecular Weight

443.95

Precautions

H315, H318, H351, H361, H372, H410

References & Citations

[1]Shibata N, et al. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands. Cancer Sci. 2017 Aug;108 (8) :1657-1666.|[2]Thappali SR, et al. Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study. Arzneimittelforschung. 2012 Dec;62 (12) :624-30.